Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Mar 13;5(1):1269.
doi: 10.13063/2327-9214.1269. eCollection 2017.

Incidence of Neutropenia in Veterans Receiving Lung Cancer Chemotherapy: A Comparison of Administrative Coding and Electronic Laboratory Data

Sarah Knerr  1 , Elaine Y Hu  2 , Steven B Zeliadt  1   2
Affiliations

Incidence of Neutropenia in Veterans Receiving Lung Cancer Chemotherapy: A Comparison of Administrative Coding and Electronic Laboratory Data

Sarah Knerr et al. EGEMS (Wash DC). .

Abstract

Introduction: The frequency of neutropenia associated with lung cancer chemotherapy outside of randomized trials is largely unknown because administrative coding underestimates its prevalence. This study compared International Classification of Diseases (ICD) diagnosis codes and electronic laboratory results, alone and in combination, for identifying neutropenia events.

Methods: Retrospective cohort study of 718 veterans receiving their first course of chemotherapy for non-small cell lung cancer. Incidence of neutropenia was assessed using electronic laboratory results and ICD-9 codes captured in the Department of Veterans Affairs (VA) electronic medical records (EMR).

Results: A total of 118 of 718 patients (16.4 percent) were identified with an absolute neutrophil count (ANC) less than 1,000 cells/mm3, while only 49 of 718 patients (6.8 percent) had ICD-9 codes for neutropenia. Using the combination of laboratory results and diagnosis codes, 136 of 718 patients (18.9 percent) experienced a neutropenic event. Compared to laboratory results as a gold standard, diagnosis codes were specific (not present for individuals without a laboratory-documented low ANC), but not sensitive (missing for many individuals with a low ANC documented in their laboratory test results).

Conclusion: Relying on ICD codes to identify neutropenia in administrative data likely results in under-reporting. The emerging availability of electronic laboratory results provides an opportunity to more accurately quantify patterns of neutropenia, identify individual risk factors, and assess clinical management practices-including use of colony-stimulating factor prophylaxis-in large community cohorts.

Keywords: administrative data; electronic health record; laboratory data; neutropenia; non-small cell lung cancer.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest The authors have no conflicts of interest to disclose. The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the United States Government.

Figures

Figure 1.
Figure 1.
Flow Diagram of Cohort Selection Note: Abbreviations - Veterans Affairs (VA); electronic medical record (EMR)
See this image and copyright information in PMC

References

    1. Lyman GH. Impact of chemotherapy does intensity on cancer patient outcomes. J Natl Compr Canc Netw. 2009;7(1):99–108. - PubMed
    1. Kuderer NM, Dale DC, Crawford J, Cosler LE, Lyman GH. Morality, morbidity, and costs associated with febrile neutropenia in adult cancer patients. Cancer. 2006;106(10):2258–66. - PubMed
    1. Potosky AL, Malin JL, Kim B, Chrischilles EA, Makgoeng SB, Howlader N, Weeks JC. Use of colony-stimulating factors with chemotherapy: opportunities for costs savings and improved outcomes. JNCI. 2011;103(12):979–982. - PMC - PubMed
    1. Sullivan SD, Ramsey SD, Blough DK, McDermott CL, Clarke L, McCune JS. Health care use and primary prophylaxis with colony-stimulating factors. Value Health. 2011;14(2):247–252. - PubMed
    1. Lewis JH, Kilgore ML, Goldman DP, Trimble EL, Kaplan R, Montello MJ, Housman MG, Escarce JJ. Participation of patients 65 years of age or older in cancer clinical trials. J Clin Oncol. 2003;21(7):1382–1389. - PubMed

LinkOut - more resources